Nuclear Medicine
OSTEOBAC
Name:
Osteobac – Radiofarma®
Active Principle:
Methylenephosphonic Acid
Therapeutic Action:
It is indicated for performing bone scintigraphy which allows evaluating areas with altered osteogenesis associated with:
1.- Neoplasia:
- Osteosarcoma staging
- Detection and monitoring of bone metastases
2.- Non-neoplastic lesions, as an aid in the evaluation of :
- Osteomyelitis
- Avascular necrosis
- Paget’s disease
- Stress fractures
- Tibial periostitis
- Detection of loose or infected prostheses when conventional radiography has already been performed and is inconclusive
- Reflex sympathetic syndrome
- Bone graft viability
Línea
Nuclear Medicine
Sublínea
SPECT Radiopharmaceuticals
OSTEOBAC
Línea
Nuclear Medicine
Sublínea
SPECT Radiopharmaceuticals
OSTEOBAC
Nuclear Medicine
OSTEOBAC
Name:
Osteobac – Radiofarma®
Active Principle:
Methylenephosphonic Acid
Therapeutic Action:
It is indicated for performing bone scintigraphy which allows evaluating areas with altered osteogenesis associated with:
1.- Neoplasia:
- Osteosarcoma staging
- Detection and monitoring of bone metastases
2.- Non-neoplastic lesions, as an aid in the evaluation of :
- Osteomyelitis
- Avascular necrosis
- Paget’s disease
- Stress fractures
- Tibial periostitis
- Detection of loose or infected prostheses when conventional radiography has already been performed and is inconclusive
- Reflex sympathetic syndrome
- Bone graft viability
RELATED PRODUCTS
-
PSMA (R+D)
PSMA (R+D)It is indicated for the detection and evaluation of prostate cancer from the initial diagnosis to the monitoring of castration-resistant metastases. -
131I MIBG BACON (R&D)
131I MIBG BACON (R&D)It is indicated for the diagnosis and location of neuroendocrine tumors, pheochromocytoma, medullary thyroid cancer, primary neuroblastomas and their metastases, paragangliomas and thymomas...